Events venue plan for former town library building
A historic former library building in Stoke-on-Trent could be brought back into use as an events venue.
Plans have been submitted to turn the old Stoke Library on London Road into a private hire venue for weddings, corporate events and community gatherings.
The Grade II listed building, known for its circular windows and William Shakespeare mosaic, is currently empty having last been used as a meditation centre.
The library service moved to a site on South Wolfe Street in 2008.
According to a planning application submitted by local resident Tariq Hussain, the plans would create a new "stylish and versatile" space while preserving one of the city's best-loved buildings.
The proposals, which also require listed building consent, would see the main hall on the ground floor serve as the primary event area.
There would also be a bar, lounge and dedicated catering area, with other rooms available for smaller events.
The lower ground floor, which has a separate entrance, could eventually be turned into a cafe.
According to the plans, the venue could have a maximum capacity of about 150 people, and be available for hire seven days a week between 09:00 and 23:00.
Alterations proposed included the division of the first-floor balcony room and the addition of a disabled toilet.
No external structural changes were planned, but fans would be added to the rear wall and front door and fencing repainted.
"The use of the building will ensure its longevity and preservation as funds raised from hiring out the hall will be used to help restore any historic elements," the application stated.
The applicant also said they would work with heritage bodies to "preserve and adapt" the building to its original design.
Planners at Stoke-on-Trent City Council are due to make a decision on the proposals in the coming weeks.
This news was gathered by the Local Democracy Reporting Service which covers councils and other public service organisations.
Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram.
Former library could be turned into flats
Views sought on plans to revamp Victorian library
Library development plans resubmitted
Stoke-on-Trent City Council
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
At a mad moment, a dull Fed is good
This article is an on-site version of our Unhedged newsletter. Premium subscribers can sign up here to get the newsletter delivered every Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Why the Netflix Stock (NFLX) Rally Isn't Done Yet
Netflix (NFLX) has soared almost 80% over the past year, recently topping $1,200 per share, prompting concerns that the stock may be overextended. Critics point to its sharp rally, driven by strong subscriber growth and bold strategic pivots, as a sign of potential overvaluation. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter But this momentum may be more than just a temporary surge. With growing strength in AI, live content, and multiple revenue streams, Netflix appears well-positioned for sustained growth. While a near-term pullback is possible given its valuation, a drop below $1,000 is unlikely. I'm strongly bullish on the cord-cutting stock that consistently disproves the naysayers. One of Netflix's most significant successes lately is the progress made in AI-powered recommendations. You're firing up Netflix and are likely to land on a show that feels like it was made for you, a great stride given that this was one aspect the company was struggling with in the past. That's the magic of Netflix's AI-driven recommendation engine, which drove 80% of content consumption last year, with subscribers averaging two hours of watch time daily. AI refines these Netflix algorithms, analyzing viewing patterns to serve up hits like Squid Game Season 2, which smashed records with 68 million views in its first week. This is great for customer satisfaction and should translate to higher retention. This is evident in churn rates holding steady despite price hikes. By personalizing content at scale, Netflix ensures subscribers stay, while, along with new cohorts coming in by the quarter, its membership and ad revenues both increase. AI is also playing a key role in driving investor enthusiasm for Netflix, as it's already transforming how content is developed and produced. From analyzing scripts for audience appeal to optimizing shooting schedules and streamlining post-production, AI allows Netflix to cut costs without compromising quality. A recent example is Carry-On, the holiday thriller that garnered 42 million views in its first week—AI helped refine its pacing to maximize viewer engagement. At the MoffettNathanson Media Conference, Netflix management emphasized how these efficiencies enable the company to deliver a wide-ranging content slate—from Guillermo del Toro's Frankenstein to Happy Gilmore 2—without inflating budgets. As Netflix plans to invest $18 billion in content in 2025, its ability to stretch production dollars through AI gives it a competitive edge. While other streamers continue to grapple with platform scalability, Netflix's proven ability to deliver high-quality originals efficiently reinforces its position as a leader in the space. Then you have Netflix's ad-supported tier, launched in 2022, which has been a runaway success, reaching 94 million monthly active users by early 2025, up from 40 million the year prior. AI is the secret sauce here, crafting ads that feel less like interruptions and more like part of the experience. You're pausing Stranger Things and seeing an advertisement for a retro diner that matches the show's vibe. AI's targeting makes that happen. We could also see Netflix rolling out AI-generated ads by next year, hyper-targeting viewers with cinematic precision. Management projects this tier could double ad revenue this year. With 45% of new sign-ups in ad-tier markets opting for this plan, Netflix is tapping a goldmine that rivals can't match. The risk here is overloading viewers with ads, which could spark backlash. However, I trust management's execution skills in this regard. Despite the excitement around Netflix's AI-driven efficiencies, the stock now trades at over 47x this year's consensus EPS estimate—an elevated valuation, even for a category leader with double-digit growth. Bears argue that a correction is overdue, and there's merit to that view. I agree that Netflix could experience a healthy pullback. However, investors waiting for a significant drop—particularly below $1,000 per share—may be waiting in vain. With consistent top-line growth and AI poised to drive long-term margin expansion, Netflix is well-positioned to sustain 20%+ annual EPS growth for the foreseeable future. Coupled with its consumer-staple-like attributes—namely, highly predictable cash flows—the company is likely to continue commanding a premium valuation. For long-term investors, Netflix remains a high-quality name that the market will be willing to pay up for. Wall Street remains highly bullish on Netflix, with a Strong Buy consensus based on 29 Buy and nine Hold ratings over the past three months, and notably, no Sell ratings. However, the average 12-month price target of $1,239.76 suggests a modest 2.2% upside from current levels. In my view, this reflects a continued underappreciation of Netflix's earnings growth potential, particularly as AI-driven efficiencies and strong content performance support long-term margin expansion. In April, Netflix reported earnings per share of $6.61, highlighting the company's current business strength with over $40 billion in revenue, more than 300 million paid households, and an audience of over 700 million individuals. Looking ahead, analysts expect NFLX to report EPS of $7.03 at its next meeting on July 17. Netflix's impressive share price rally reflects growing investor confidence in its ability to harness AI to boost revenue and reduce costs. From AI-enhanced user engagement and efficient content production to the rapid growth of its ad-supported tier, Netflix is increasingly viewed as the undisputed leader in the streaming space, with the potential for even greater dominance ahead. While the stock's valuation is undeniably elevated, the company's strong earnings trajectory suggests that a significant pullback is unlikely in the near term. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
